secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2022-01-26T23:59:59+00:00
Accession:  0000875320-22-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex reports Q4 2021 product revenue $2.07B (+27% YoY); guides 2022 revenue $8.4-$8.6B
--------------------------------------------------------------------------------

- Full-year 2021 product revenue $7.57B (+22% YoY); GAAP diluted EPS $9.01, Non-GAAP $13.02.
- Q4 2021 GAAP net income $770M ($3.00 diluted EPS); Non-GAAP $866M ($3.37).
- FY 2022 product revenue guidance $8.4-$8.6B; combined Non-GAAP R&D+SG&A $2.70-$2.75B.
- KAFTRIO approved in EU/UK for CF children 6-11; new reimbursement agreements in Spain and Netherlands.
- Pipeline: VX-147 AMKD Phase 2 POC met; VX-880 T1D Day 150 data shows insulin reduction; CTX001 enrollment complete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000003/0000875320-22-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000003/vrtx-20220126.htm
  HTML page:      https://secwatch.observer/filing/0000875320-22-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer